Uniqure receives fda regenerative medicine advanced therapy (rmat) designation for investigational gene therapy amt-130 in huntington's disease

~ designation based on 24-month interim phase i/ii clinical data for amt-130 announced in december 2023 ~ ~ amt-130 is the first therapeutic candidate to receive rmat designation for huntington's disease ~ ~ receiving rmat designation enables increased collaboration with the fda on regulatory approval planning, in addition to the opportunity for expedited product development ~ lexington, mass. and amsterdam, june 03, 2024 (globe newswire) -- uniqure n.v.
AMT Ratings Summary
AMT Quant Ranking